-
2
-
-
77953549604
-
Mortality and causes of death in Italian persons with haemophilia, 1990-2007
-
Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
-
(2010)
Haemophilia
, vol.16
, pp. 437-446
-
-
Tagliaferri, A.1
Rivolta, G.F.2
Iorio, A.3
-
4
-
-
79953306825
-
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
-
Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 700-710
-
-
Gringeri, A.1
Lundin, B.2
Von MacKensen, S.3
-
5
-
-
84860520021
-
Prophylaxis in haemophilia should be life-long
-
Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
-
(2012)
Blood Transfus
, vol.10
, pp. 165-168
-
-
Makris, M.1
-
6
-
-
4844222412
-
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden
-
DOI 10.1111/j.1365-2516.2004.00952.x
-
Carlsson KS, Hojgard S, Lindgren A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26. (Pubitemid 39317762)
-
(2004)
Haemophilia
, vol.10
, Issue.5
, pp. 515-526
-
-
Steen Carlsson, K.1
Hojgard, S.2
Lindgren, A.3
Lethagen, S.4
Schulman, S.5
Glomstein, A.6
Tengborn, L.7
Berntorp, E.8
Lindgren, B.9
-
7
-
-
80052262310
-
Haemophilia: Provision of factors and novel therapies: World Federation of Hemophilia goals and achievements
-
Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; 154: 704-14.
-
(2011)
Br J Haematol
, vol.154
, pp. 704-714
-
-
Skinner, M.W.1
-
8
-
-
84885580434
-
The demand for factor VIII and for factor IX and the toll fractionation product surplus management
-
Calizzani G, Profili S, Candura F, et al. The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 2013; 11 (Suppl 4): s64-76.
-
(2013)
Blood Transfus
, vol.11
, Issue.SUPPL. 4
-
-
Calizzani, G.1
Profili, S.2
Candura, F.3
-
9
-
-
84885670125
-
Plasma and plasmaderived medicinal products self-sufficiency: The Italian case
-
Calizzani G, Profili S, Candura F, et al. Plasma and plasmaderived medicinal products self-sufficiency: the Italian case. Blood Transfus 2013; 11 (Suppl 4): s118-31.
-
(2013)
Blood Transfus
, vol.11
, Issue.SUPPL. 4
-
-
Calizzani, G.1
Profili, S.2
Candura, F.3
-
10
-
-
84879464631
-
Models for institutional and professional accreditation of haemophilia centres in Italy
-
Calizzani G, Vaglio S, Arcieri R, et al. Models for institutional and professional accreditation of haemophilia centres in Italy. Haemophilia 2013; 19: e248-55.
-
(2013)
Haemophilia
, vol.19
-
-
Calizzani, G.1
Vaglio, S.2
Arcieri, R.3
-
11
-
-
40349091533
-
European principles of haemophilia care
-
DOI 10.1111/j.1365-2516.2007.01625.x
-
Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74. (Pubitemid 351338698)
-
(2008)
Haemophilia
, vol.14
, Issue.2
, pp. 361-374
-
-
Colvin, B.T.1
Astermark, J.2
Fischer, K.3
Gringeri, A.4
Lassila, R.5
Schramm, W.6
Thomas, A.7
Ingerslev, J.8
-
13
-
-
84860499640
-
Prophylaxis for adults with haemophilia: Towards a personalised approach?
-
Franchini M, Mannucci PM. Prophylaxis for adults with haemophilia: towards a personalised approach? Blood Transfus 2012; 10: 123-4.
-
(2012)
Blood Transfus
, vol.10
, pp. 123-124
-
-
Franchini, M.1
Mannucci, P.M.2
-
14
-
-
84860531391
-
Prophylaxis for adults with haemophilia: One size does not fit all
-
Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
-
(2012)
Blood Transfus
, vol.10
, pp. 169-173
-
-
Fischer, K.1
-
15
-
-
84860348922
-
Past, present and future of hemophilia: A narrative review
-
Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
-
(2012)
Orphanet J Rare Dis
, vol.7
, pp. 24
-
-
Franchini, M.1
Mannucci, P.M.2
-
16
-
-
84883798278
-
Randomized, controlled, parallel-group trial of routine prophylaxis vs. On-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
-
Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 1119-1127
-
-
Manco-Johnson, M.J.1
Kempton, C.L.2
Reding, M.T.3
-
17
-
-
78049278337
-
Awaiting evidence-based recommendations on prophylaxis in adult patients
-
Tagliaferri A. Awaiting evidence-based recommendations on prophylaxis in adult patients. Haemophilia 2010; 16: 955-6.
-
(2010)
Haemophilia
, vol.16
, pp. 955-956
-
-
Tagliaferri, A.1
-
18
-
-
37149022850
-
Factor VIII products and inhibitor development: The SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
-
Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: S65-8.
-
(2007)
Haemophilia
, vol.13
-
-
Mannucci, P.M.1
Gringeri, A.2
Peyvandi, F.3
Santagostino, E.4
-
19
-
-
84879333376
-
New challenges in hemophilia: Long-term outcomes and complications
-
Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program 2012; 2012: 362-8.
-
(2012)
Hematology Am Soc Hematol Educ Program
, vol.2012
, pp. 362-368
-
-
Young, G.1
-
20
-
-
79960142103
-
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy
-
Giampaolo A, Abbonizio F, Puopolo M, et al. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011; 21(4): 280-4.
-
(2011)
Transfus Med
, vol.21
, Issue.4
, pp. 280-284
-
-
Giampaolo, A.1
Abbonizio, F.2
Puopolo, M.3
-
21
-
-
80052669248
-
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B
-
Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
-
(2011)
Blood
, vol.118
, pp. 2695-2701
-
-
Negrier, C.1
Knobe, K.2
Tiede, A.3
-
22
-
-
84859974586
-
The hope and reality of long-acting hemophilia products
-
Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87: S33-9.
-
(2012)
Am J Hematol
, vol.87
-
-
Pipe, S.W.1
-
23
-
-
78049285843
-
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: Plasmaderived is better
-
Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasmaderived is better. Blood Transfus 2010; 8: 288-91.
-
(2010)
Blood Transfus
, vol.8
, pp. 288-291
-
-
Mannucci, P.M.1
-
24
-
-
78049271862
-
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: Recombinant is better
-
Franchini M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.
-
(2010)
Blood Transfus
, vol.8
, pp. 292-296
-
-
Franchini, M.1
-
25
-
-
84855740554
-
Clinical and organisational aspects of haemophilia care: The patients' view
-
Calizzani G, Arcieri R. Clinical and organisational aspects of haemophilia care: the patients' view. Blood Transfus 2012; 10: 110-1.
-
(2012)
Blood Transfus
, vol.10
, pp. 110-111
-
-
Calizzani, G.1
Arcieri, R.2
-
26
-
-
80054883005
-
Factor VIII safety: Plasma-derived versus recombinant products
-
Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011; 9: 366-70.
-
(2011)
Blood Transfus
, vol.9
, pp. 366-370
-
-
Gringeri, A.1
-
27
-
-
84860767903
-
How we choose factor VIII to treat hemophilia
-
Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
-
(2012)
Blood
, vol.119
, pp. 4108-4114
-
-
Mannucci, P.M.1
Mancuso, M.E.2
Santagostino, E.3
-
28
-
-
27744504877
-
Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment
-
DOI 10.1111/j.1365-2516.2005.01159.x
-
Mantovani LG, Monzini M, Mannucci PM, et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11: 589-97. (Pubitemid 41631593)
-
(2005)
Haemophilia
, vol.11
, Issue.6
, pp. 589-597
-
-
Mantovani, L.G.1
Monzini, M.S.2
Mannucci, P.M.3
Scalone, L.4
Villa, M.5
Gringeri, A.6
Barillari, G.7
Baudo, F.8
Billio, A.9
Bizzoni, L.10
Boeri, E.11
Caputo, B.12
Castaman, G.13
Contino, L.14
Delios, G.15
Coppola, A.16
Dragani, A.17
Feola, G.18
Bertuzzo, D.19
D'Inca, M.20
Santagostino, E.21
Iannaccaro, P.22
Iorio, A.23
Mancuso, G.24
Morfini, M.25
Musso, R.26
Piseddu, G.27
Rocino, A.28
Rodorigo, G.29
Rossetti, G.30
Scaraggi, F.A.31
Schiavoni, M.32
Schinco, P.33
Tagariello, G.34
Tagliaferri, A.35
Targhetta, R.36
Lombardo, V.T.37
Zanon, E.38
more..
-
29
-
-
84865560607
-
Haemophilia care in Europe: The ESCHQoL study
-
Schramm W, Gringeri A, Ljung R, et al. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012; 18: 729-37.
-
(2012)
Haemophilia
, vol.18
, pp. 729-737
-
-
Schramm, W.1
Gringeri, A.2
Ljung, R.3
-
30
-
-
84885674108
-
-
(gennaio - settembre 2012). Roma, gennaio. Osservatorio Nazionale sull'Impiego dei Medicinali. Accessed on 21/08/2013
-
L'uso dei farmaci in Italia - Rapporto OsMed (gennaio - settembre 2012). Roma, gennaio 2013. Osservatorio Nazionale sull'Impiego dei Medicinali. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto- osmed2012.pdf. Accessed on 21/08/2013.
-
(2013)
L'Uso Dei Farmaci in Italia - Rapporto OsMed
-
-
-
33
-
-
84885672815
-
-
7 June. Accessed on 21/08/2013
-
European guidelines for the certification of Haemophilia Centres, 7 June 2013. Available at: http://www.euhanet.org/docs/Euhanet-European-guidelines-for- the-certification-of-Haemophilia-Centres-2013.pdf. Accessed on 21/08/2013.
-
(2013)
European Guidelines for the Certification of Haemophilia Centres
-
-
-
34
-
-
27644457882
-
A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders
-
DOI 10.2105/AJPH.2004.051318
-
Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005; 95: 1910-6. (Pubitemid 41572360)
-
(2005)
American Journal of Public Health
, vol.95
, Issue.11
, pp. 1910-1916
-
-
Baker, J.R.1
Crudder, S.O.2
Riske, B.3
Bias, V.4
Forsberg, A.5
-
35
-
-
84885608483
-
The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy
-
Calizzani G, Vaglio S, Candura F, et al. The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy. Blood Transfus 2013; 11 (Suppl 4): s6-12.
-
(2013)
Blood Transfus
, vol.11
, Issue.SUPPL. 4
-
-
Calizzani, G.1
Vaglio, S.2
Candura, F.3
-
36
-
-
84883049423
-
st century through competitive tendering
-
DOI: 10.1111/hae.12169
-
st century through competitive tendering. Haemophilia 2013; DOI: 10.1111/hae.12169.
-
(2013)
Haemophilia
-
-
Hay, C.R.1
-
37
-
-
84872450786
-
Factor VIII products and inhibitor development in severe hemophilia A
-
Gouw SC, Van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. NEJM 2013; 368: 231-9.
-
(2013)
NEJM
, vol.368
, pp. 231-239
-
-
Gouw, S.C.1
Van Der-Bom, J.G.2
Ljung, R.3
-
38
-
-
79959486802
-
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
-
Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
-
(2011)
Blood
, vol.117
, pp. 6367-6370
-
-
Hay, C.R.1
Palmer, B.2
Chalmers, E.3
-
39
-
-
84883053783
-
On behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: A prospective, controlled study
-
Hay CR, Palmer B, Chalmers E et al., on behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: a prospective, controlled study. Haemophilia 2012; 18: 828.
-
(2012)
Haemophilia
, vol.18
, pp. 828
-
-
Hay, C.R.1
Palmer, B.2
Chalmers, E.3
-
40
-
-
84887121716
-
Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers
-
DOI:10.1016/j.healthpol.2013.05.022
-
Morgan SG, Thomson PA, Daw JR, Friesen, MK. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy 2013; DOI: 10.1016/j. healthpol.2013.05.022.
-
(2013)
Health Policy
-
-
Morgan, S.G.1
Thomson, P.A.2
Daw, J.R.3
Friesen, M.K.4
-
41
-
-
84881669041
-
Performancebased risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force
-
Garrison LP Jr, Towse A, Briggs A, et al. Performancebased risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013; 16: 703-19.
-
(2013)
Value Health
, vol.16
, pp. 703-719
-
-
Garrison Jr., L.P.1
Towse, A.2
Briggs, A.3
|